302 related articles for article (PubMed ID: 10846104)
1. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.
Gorny MK; Zolla-Pazner S
J Virol; 2000 Jul; 74(13):6186-92. PubMed ID: 10846104
[TBL] [Abstract][Full Text] [Related]
2. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of four novel monoclonal antibodies specific to N51(L6)C46 polypeptide simulating fusogenic core structure of GP41 subunit of HIV-1.
Chen Z; Hong L; Li Z; Fan D; Huang Q; Wang H; Li Z; Xu Z
Hybridoma (Larchmt); 2006 Oct; 25(5):278-82. PubMed ID: 17044783
[TBL] [Abstract][Full Text] [Related]
4. Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.
Gustchina E; Bewley CA; Clore GM
J Virol; 2008 Oct; 82(20):10032-41. PubMed ID: 18667502
[TBL] [Abstract][Full Text] [Related]
5. Progress towards the development of a HIV-1 gp41-directed vaccine.
McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
[TBL] [Abstract][Full Text] [Related]
6. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
[TBL] [Abstract][Full Text] [Related]
7. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
[TBL] [Abstract][Full Text] [Related]
8. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.
Xu JY; Gorny MK; Palker T; Karwowska S; Zolla-Pazner S
J Virol; 1991 Sep; 65(9):4832-8. PubMed ID: 1714520
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
Neurath AR; Strick N; Lin K; Jiang S
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
[TBL] [Abstract][Full Text] [Related]
10. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
Nelson JD; Brunel FM; Jensen R; Crooks ET; Cardoso RM; Wang M; Hessell A; Wilson IA; Binley JM; Dawson PE; Burton DR; Zwick MB
J Virol; 2007 Apr; 81(8):4033-43. PubMed ID: 17287272
[TBL] [Abstract][Full Text] [Related]
11. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.
Huarte N; Lorizate M; Maeso R; Kunert R; Arranz R; Valpuesta JM; Nieva JL
J Virol; 2008 Sep; 82(18):8986-96. PubMed ID: 18596094
[TBL] [Abstract][Full Text] [Related]
12. Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.
Yuan W; Li X; Kasterka M; Gorny MK; Zolla-Pazner S; Sodroski J
AIDS Res Hum Retroviruses; 2009 Mar; 25(3):319-28. PubMed ID: 19292593
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PW
J Virol; 2001 Nov; 75(22):10892-905. PubMed ID: 11602729
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
Conley AJ; Kessler JA; Boots LJ; Tung JS; Arnold BA; Keller PM; Shaw AR; Emini EA
Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3348-52. PubMed ID: 7512731
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
Menendez A; Chow KC; Pan OC; Scott JK
J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
[TBL] [Abstract][Full Text] [Related]
16. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody.
Jiang S; Lin K; Zhang L; Debnath AK
J Virol Methods; 1999 Jun; 80(1):85-96. PubMed ID: 10403680
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
Alam SM; Scearce RM; Parks RJ; Plonk K; Plonk SG; Sutherland LL; Gorny MK; Zolla-Pazner S; Vanleeuwen S; Moody MA; Xia SM; Montefiori DC; Tomaras GD; Weinhold KJ; Karim SA; Hicks CB; Liao HX; Robinson J; Shaw GM; Haynes BF
J Virol; 2008 Jan; 82(1):115-25. PubMed ID: 17942537
[TBL] [Abstract][Full Text] [Related]
18. Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.
Liu J; Deng Y; Li Q; Dey AK; Moore JP; Lu M
J Virol; 2010 Jan; 84(1):201-9. PubMed ID: 19846514
[TBL] [Abstract][Full Text] [Related]
19. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
20. Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity.
Huarte N; Araujo A; Arranz R; Lorizate M; Quendler H; Kunert R; Valpuesta JM; Nieva JL
PLoS One; 2012; 7(12):e52740. PubMed ID: 23285173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
